dc.contributor.author | Bozkurt, Mehmet Abdussamet | |
dc.contributor.author | Afsar, Cigdem Usul | |
dc.contributor.author | Serilmez, Murat | |
dc.contributor.author | Karabulut, Senem | |
dc.contributor.author | Karabulut, Mehmet | |
dc.contributor.author | Alis, Halil | |
dc.contributor.author | Tas, Faruk | |
dc.contributor.author | Aydogan, Fatma | |
dc.date.accessioned | 2021-03-03T08:00:08Z | |
dc.date.available | 2021-03-03T08:00:08Z | |
dc.identifier.citation | Karabulut S., Afsar C. U. , Karabulut M., Alis H., Bozkurt M. A. , Aydogan F., Serilmez M., Tas F., "Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma", BBA CLINICAL, cilt.6, ss.138-142, 2016 | |
dc.identifier.other | av_151cd769-be63-4444-8d50-5e0dedda4073 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/19574 | |
dc.identifier.uri | https://doi.org/10.1016/j.bbacli.2016.10.002 | |
dc.description.abstract | Background: Omentin is related with metabolic syndrome and obesity. Pancreatic adenocarcinoma (PA) is a lethal and obesity-linked malignancy. This study was conducted to investigate the serum levels of omentin in patients with PA and the relationship with tumor progression and known prognostic parameters. | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp | |
dc.subject | TIP, GENEL & İÇECEK | |
dc.title | Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma | |
dc.type | Makale | |
dc.relation.journal | BBA CLINICAL | |
dc.contributor.department | Istanbul Training & Research Hospital , , | |
dc.identifier.volume | 6 | |
dc.identifier.startpage | 138 | |
dc.identifier.endpage | 142 | |
dc.contributor.firstauthorID | 237410 | |